Business ❯ Healthcare ❯ Biotechnology

Regulatory Affairs

FDA Approval FDA Compliance

Atara Biotherapeutics Hit With Investor Class Action as Firms Press May 22 Lead-Plaintiff Deadline

Investor lawyers say FDA setbacks tied to trial design flaws drove investor losses.

FDA Signals Openness to Accelerated Path for Lexeo’s Friedreich’s Ataxia Cardiac Gene Therapy